Financials · VMD

Viemed Healthcare Inc. (VMD) financials

For the twelve months ended Sep 30, 2026, Viemed Healthcare Inc. reported $310.37M of revenue and $15.89M of net income.

Revenue, TTM
$310.37M
Revenue growth, YoY
+21.8%
Net income, TTM
$15.89M
Net income growth, YoY
+15.2%
Net margin
5.1%
Free cash flow, TTM
$21.38M
EPS, diluted, TTM
$0.38
EPS growth, YoY
+15.2%
Cash
$9.68M
Total debt
$5.02M
P/E
21.77
P/S
1.11
Market cap
$346.0M
Annual revenue$270.28M
FY2018FY2025
Annual net income$14.93M
FY2018FY2025
Annual free cash flow$11.93M
FY2018FY2025

VMD revenue and earnings growth

VMD revenueQ3 2026$80.67M

Quarter YoY
+12.2%
QoQ
+3.3%
FY YoY
+20.5%
5Y CAGR
+15.5%

VMD revenue was $80.67M in fiscal Q3 2026 (ended Sep 30, 2026), up 12.2% from a year earlier and up 3.3% from the prior quarter. For the full fiscal 2025 it was $270.28M, up 20.5% from fiscal 2024. Compound annual growth was +15.5% over 5 years. It rose in 6 of the last 7 fiscal years. Fiscal 2025 is the highest of the 8 fiscal years on file.

VMD net incomeQ3 2026$4.64M

Quarter YoY
+32.0%
QoQ
+59.9%
FY YoY
+32.6%
5Y CAGR
-13.9%

VMD net income was $4.64M in fiscal Q3 2026 (ended Sep 30, 2026), up 32.0% from a year earlier and up 59.9% from the prior quarter. For the full fiscal 2025 it was $14.93M, up 32.6% from fiscal 2024. Compound annual growth was -13.9% over 5 years. It rose in 4 of the last 7 fiscal years.

VMD EPSQ3 2026$0.11

Quarter YoY
+22.2%
QoQ
+57.1%
FY YoY
+32.1%
5Y CAGR
-13.9%

VMD diluted EPS was $0.11 in fiscal Q3 2026 (ended Sep 30, 2026), up 22.2% from a year earlier and up 57.1% from the prior quarter. For the full fiscal 2025 it was $0.37, up 32.1% from fiscal 2024. Compound annual growth was -13.9% over 5 years.

VMD free cash flowQ3 2026$2.87M

Quarter YoY
-73.2%
QoQ
-61.4%
FY YoY
+805.2%
5Y CAGR
-11.6%

VMD free cash flow was $2.87M in fiscal Q3 2026 (ended Sep 30, 2026), down 73.2% from a year earlier and down 61.4% from the prior quarter. For the full fiscal 2025 it was $11.93M, up 805.2% from fiscal 2024. Compound annual growth was -11.6% over 5 years. It rose in 4 of the last 7 fiscal years.

Export CSV

Income statement

Income statement
Line item
Dec 31, 2025
Dec 31, 2024
Dec 31, 2023
Dec 31, 2022
Dec 31, 2021
Dec 31, 2020
Dec 31, 2019
Dec 31, 2018
Revenue$270.28M$224.26M$183.01M$138.83M$117.06M$131.31M$80.26M$64.46M
Cost of revenue$114.82M$91.05M$70.22M$54.15M$43.65M$51.20M$24.25M$16.69M
Gross profit$155.46M$133.20M$112.78M$84.68M$73.41M$80.11M$56.01M$47.77M
Research and development$3.02M$3.07M$2.78M$2.70M$2.11M$1.08M$848.0K$0
Selling, general and admin$121.37M$106.20M$87.88M$68.16M$54.89M$52.83M$41.38M$34.30M
Operating income$22.95M$17.90M$14.33M$8.25M$11.58M$26.78M$8.86M$10.06M
Pre-tax income$21.77M$16.17M$14.39M$8.99M$12.50M$26.36M$8.80M$9.67M
Income tax$6.39M$4.76M$4.15M$2.77M$3.38M-$5.17M$271.0K$162.0K
Net income$14.93M$11.27M$10.24M$6.22M$9.13M$31.53M$8.53M$9.51M
EPS, basic$0.38$0.29$0.27$0.16$0.23$0.81$0.23$0.25
EPS, diluted$0.37$0.28$0.25$0.16$0.22$0.78$0.21$0.24
Diluted shares40.8M40.8M40.4M39.8M40.7M40.5M39.7M39.7M

Balance sheet

Balance sheet
Line item
Dec 31, 2025
Dec 31, 2024
Dec 31, 2023
Dec 31, 2022
Dec 31, 2021
Dec 31, 2020
Dec 31, 2019
Dec 31, 2018
Cash and equivalents$13.50M$17.54M$12.84M$16.91M$28.41M$30.98M$13.36M$10.41M
Receivables$25.59M$24.91M$18.45M$15.38M$12.82M$12.37M$11.53M$8.84M
Inventory$5.05M$4.32M$4.63M$3.57M$2.46M$2.31M$1.36M$2.89M
Current assets$48.49M$52.88M$38.37M$39.74M$47.31M$47.17M$27.81M$23.09M
Goodwill$58.94M$32.99M$29.77M$0----
Total assets$199.15M$177.07M$154.90M$117.04M$117.96M$112.56M$82.60M$53.65M
Current liabilities$41.06M$37.33M$32.12M$18.86M$17.81M$23.02M$25.91M$19.57M
Short-term debt$1.09M$409.0K$1.07M$0$1.48M$1.84M$1.75M$0
Long-term debt$11.29M$3.59M$6.00M$0$4.31M$5.80M$7.63M$0
Total debt$12.38M$4.00M$7.07M$0$5.79M$7.63M$9.38M$0
Total liabilities$55.63M$43.77M$41.00M$19.95M$23.14M$30.87M$38.90M$21.08M
Shareholders' equity$141.54M$133.30M$113.89M$97.09M$94.82M$81.69M$43.70M$32.57M

Cash flow

Cash flow
Line item
Dec 31, 2025
Dec 31, 2024
Dec 31, 2023
Dec 31, 2022
Dec 31, 2021
Dec 31, 2020
Dec 31, 2019
Dec 31, 2018
Operating cash flow$51.92M$39.09M$45.21M$27.75M$22.49M$35.11M$19.09M$22.37M
Capital expenditures$39.98M$37.77M$26.09M$22.90M$19.74M$13.04M$13.38M$6.11M
Free cash flow$11.93M$1.32M$19.12M$4.85M$2.75M$22.07M$5.70M$16.25M
Investing cash flow-$50.17M-$30.70M-$52.11M-$23.98M-$19.75M-$8.41M-$12.81M-$5.30M
Financing cash flow-$5.79M-$3.69M$2.83M-$15.27M-$5.32M-$9.07M-$3.33M-$11.75M
Share repurchases$13.22M$0$0$9.57M$0$0$1.52M$1.59M
Stock-based compensation$9.13M$6.29M$5.85M$5.20M$5.15M$4.88M$3.89M$2.70M
Depreciation and amortization$28.61M$25.37M$21.86M$15.63M----

Key ratios

Key ratios
Line item
Dec 31, 2025
Dec 31, 2024
Dec 31, 2023
Dec 31, 2022
Dec 31, 2021
Dec 31, 2020
Dec 31, 2019
Dec 31, 2018
Revenue growth, YoY20.5%22.5%31.8%18.6%-10.8%63.6%24.5%-
Net income growth, YoY32.6%10.0%64.6%-31.8%-71.1%269.9%-10.3%-
EPS growth, YoY32.1%12.0%56.3%-27.3%-71.8%271.4%-12.5%-
Gross margin57.5%59.4%61.6%61.0%62.7%61.0%69.8%74.1%
Operating margin8.5%8.0%7.8%5.9%9.9%20.4%11.0%15.6%
Net margin5.5%5.0%5.6%4.5%7.8%24.0%10.6%14.7%
Free cash flow margin4.4%0.6%10.4%3.5%2.4%16.8%7.1%25.2%
Return on equity10.6%8.5%9.0%6.4%9.6%38.6%19.5%29.2%
Return on assets7.5%6.4%6.6%5.3%7.7%28.0%10.3%17.7%
Current ratio1.181.421.192.112.662.051.071.18
Debt to equity0.090.030.060.000.060.090.210.00

Source: XBRL data Viemed Healthcare Inc. files with the SEC, latest filing dated Nov 4, 2026 (see filings on SEC EDGAR). Provided for information only, not investment advice. Check the filing before relying on a number.

* Worked out from the filings rather than stated in them: Q4 is the full year less the first nine months.

Per-share figures are as filed. The filings show no stock split in these periods.

EPS growth is left out where the share count moved enough to suggest a split the filings do not show. Growth rates need a positive starting figure. CAGR is compound annual growth between fiscal years. The CSV holds every period on file, in full figures, from the same SEC filings.

VMD peers

CompanyRevenueGrowthNet incomeNet marginMarket cap
VMD$310.37M+21.8%$15.89M5.1%$346.0M
FMS€19.63B+1.5%€978.37M5.0%$13.07B
DVA$14.17B+6.4%$920.08M6.5%$12.04B
SHC$1.23B+6.9%$173.47M14.1%$4.57B
PGNY$1.34B+5.5%$91.02M6.8%$2.67B
AGL$6.00B+2.0%-$87.10M-1.5%$1.90B
CCEL$31.13M-2.0%-$1.95M-6.2%$39.4M
NIVF$23.71M+336.3%$9.88M41.7%$4.5M

VMD FAQ

9 questions
  • What is VMD revenue?
    Viemed Healthcare Inc. (VMD) reported $310.37M of revenue for the twelve months ended Sep 30, 2026. That is up 21.8% from the year before. Revenue for fiscal 2025 was $270.28M.
  • Is VMD profitable?
    Yes. Viemed Healthcare Inc. earned $15.89M in net income for the twelve months ended Sep 30, 2026, a net margin of 5.1%.
  • How much cash and debt does VMD have?
    Viemed Healthcare Inc. reported $9.68M in cash and cash equivalents and $5.02M of debt on its most recent balance sheet in SEC filings.
  • How fast is VMD revenue growing?
    Viemed Healthcare Inc.'s revenue changed +20.5% in fiscal 2025, to $270.28M. Its compound annual growth rate was +15.5% over 5 years.
  • What is VMD gross margin?
    Viemed Healthcare Inc.'s gross profit was $178.17M on $310.37M of revenue for the twelve months ended Sep 30, 2026, a gross margin of 57.4%.
  • What is VMD free cash flow?
    Viemed Healthcare Inc. generated $21.38M of free cash flow for the twelve months ended Sep 30, 2026, which is operating cash flow of $53.90M less capital expenditures.
  • What is VMD earnings per share?
    Diluted earnings per share were $0.38 for the twelve months ended Sep 30, 2026, from SEC filings, restated for any stock split those filings show.
  • When did VMD last report financial results?
    The latest statements here come from Viemed Healthcare Inc.'s 10-Q filed on Nov 4, 2026, covering the period ended Sep 30, 2026.
  • Where does this VMD financial data come from?
    Quantisnow builds these statements from the structured XBRL data Viemed Healthcare Inc. files with the SEC. It is provided for information only and is not investment advice.